OncoCyte Corp (OCX)
2.65
-0.13
(-4.66%)
USD |
NASDAQ |
May 03, 10:25
OncoCyte Enterprise Value: 27.64M for May 2, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 02, 2024 | 27.64M |
| May 01, 2024 | 24.58M |
| April 30, 2024 | 23.78M |
| April 29, 2024 | 24.25M |
| April 26, 2024 | 23.65M |
| April 25, 2024 | 23.11M |
| April 24, 2024 | 23.38M |
| April 23, 2024 | 23.31M |
| April 22, 2024 | 24.05M |
| April 19, 2024 | 23.91M |
| April 18, 2024 | 24.71M |
| April 17, 2024 | 25.11M |
| April 16, 2024 | 27.25M |
| April 15, 2024 | 24.31M |
| April 12, 2024 | 12.99M |
| April 11, 2024 | 15.10M |
| April 10, 2024 | 14.62M |
| April 09, 2024 | 14.64M |
| April 08, 2024 | 14.56M |
| April 05, 2024 | 14.56M |
| April 04, 2024 | 14.89M |
| April 03, 2024 | 14.89M |
| April 02, 2024 | 14.77M |
| April 01, 2024 | 15.19M |
| March 28, 2024 | 14.77M |
| Date | Value |
|---|---|
| March 27, 2024 | 15.19M |
| March 26, 2024 | 15.33M |
| March 25, 2024 | 15.50M |
| March 22, 2024 | 15.85M |
| March 21, 2024 | 15.76M |
| March 20, 2024 | 15.93M |
| March 19, 2024 | 15.35M |
| March 18, 2024 | 15.52M |
| March 15, 2024 | 15.19M |
| March 14, 2024 | 14.94M |
| March 13, 2024 | 15.43M |
| March 12, 2024 | 15.43M |
| March 11, 2024 | 15.02M |
| March 08, 2024 | 15.35M |
| March 07, 2024 | 15.35M |
| March 06, 2024 | 15.43M |
| March 05, 2024 | 15.52M |
| March 04, 2024 | 15.35M |
| March 01, 2024 | 15.35M |
| February 29, 2024 | 14.61M |
| February 28, 2024 | 15.02M |
| February 27, 2024 | 15.02M |
| February 26, 2024 | 15.76M |
| February 23, 2024 | 15.89M |
| February 22, 2024 | 15.75M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-2.336M
Minimum
Dec 20 2022
565.53M
Maximum
Feb 16 2021
126.34M
Average
85.72M
Median
Enterprise Value Benchmarks
| Fonar Corp | 44.78M |
| XWELL Inc | -7.676M |
| ProPhase Labs Inc | 106.83M |
| Applied DNA Sciences Inc | 0.0538M |
| Veracyte Inc | 1.299B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -15.99M |
| Revenue (Quarterly) | 0.314M |
| Total Expenses (Quarterly) | 5.369M |
| EPS Diluted (Quarterly) | -2.07 |
| Gross Profit Margin (Quarterly) | -37.26% |
| Profit Margin (Quarterly) | -5.09K% |
| Earnings Yield | -134.0% |
| Normalized Earnings Yield | -129.33 |